COMPANY INFO
Matter Bio is a biotechnology company founded in 2022 and headquartered in New York, NY. It was co-founded by Christopher Bradley and George Church, PhD, and employs around 6-8 people. The company focuses on longevity through DNA information preservation by developing biotechnology research services aimed at countering genome information loss to increase patient longevity through mutation reversal.
Matter Bio is a biotechnology company founded in 2022 and headquartered in Brooklyn, New York. Co-founded by Christopher Bradley and renowned geneticist George Church, Matter Bio focuses on extending human longevity by developing technologies for DNA information preservation and mutation reversal. With a team of 6–8 employees, Matter Bio advances research in genome information loss and its role in aging, aiming to increase patient lifespan through innovative biotechnology research services.
Matter Bio funding has been instrumental in driving the company's ambitious mission. Since its inception, Matter Bio has raised a total of $9.15 million across 3 funding rounds, with support from both prominent institutional investors and angel investors in the biotechnology sector. Key financial milestones include their substantial Series A and follow-on Seed rounds. The funding strategy centers around raising capital for research into the information theory of aging, supporting clinical trials, and advancing breakthroughs in personalized medicine related to genomic integrity. This approach has allowed Matter Bio to rapidly develop its core technologies and prepare for clinical advancement.
This latest Seed round is aimed at advancing research and developing solutions for genome integrity and longevity preservation, enabling breakthroughs in personalized medicine and aging.
The Series A round was raised to accelerate product development and scale Matter Bio’s operations, supporting their move from research into broader market and clinical applications.
The initial Seed funding was dedicated to launching the company and supporting early-stage research and development initiatives.
Google Ventures is a leading venture capital firm that specializes in funding innovative technology companies. As a key investor, Google Ventures led Matter Bio's Series A round and continues to support the company as it advances its biotechnology platforms and product pipeline.
Shrug Capital participated in the Series A round alongside Google Ventures, providing strategic guidance and financial support to fuel Matter Bio's growth.
Y Combinator is a renowned startup accelerator. It backed Matter Bio’s early Seed round, helping launch the company and position it for future funding success.
LifeSpan Vision Ventures led the most recent Seed round, supporting Matter Bio's mission to extend human healthspan through longevity science and genomics.
Formic Ventures is known for investing in emerging biotech and life sciences startups. The firm has contributed capital and expertise to Matter Bio, fueling continued innovation.
ODF is another venture capital partner that supports Matter Bio in developing advanced biotechnology approaches to DNA preservation and aging.
quadraScope Ventures participated in the latest funding round, contributing resources aimed at advancing Matter Bio’s cutting-edge research and clinical trials.
Websets is a powerful natural language search and data enrichment tool that helps you discover comprehensive funding information for any company. Whether you're researching Matter Bio funding rounds or exploring investment data for other companies, Websets provides detailed insights into funding history, investors, and financial milestones.
With Websets, you can access detailed funding profiles, investor information, and financial data through intuitive natural language queries. Sign up now to enhance your funding research capabilities.